UNSPSC 51271916: Chloroprocaine hydrochloride

This classification denotes an anesthetic agent with the molecular formula C13H19ClN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier LT7Z1YW11H, chemically known as benzoic acid, 4-amino-2-chloro-, 2-(diethylamino)ethyl ester, monohydrochloride but more generally known as chloroprocaine hydrochloride, which bears US NIH Compound Identifier 19727. European Medicines Agency schedules Chloroprocaine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01232MIG.

UNSPSC 51271916 Chloroprocaine hydrochloride is a Commodity code covering local anesthetic pharmaceutical products supplied through state and local government cooperative purchasing agreements and healthcare facilities. State and local governments procure this product primarily through multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions and establish master contracts with pharmaceutical manufacturers and wholesalers, reducing per-unit costs and standardizing supply chains for public health systems, hospitals, clinics, and emergency medical services. Issuing bodies for products under this code include state departments of administration acting through cooperative purchasing offices (such as the Minnesota Department of Administration administering the MMCAP alliance), participating state and local healthcare agencies, and member jurisdictions within multistate purchasing consortiums. Cooperatives function as aggregation vehicles, meaning a single RFP may serve dozens of member states, counties, cities, and special districts simultaneously rather than each jurisdiction issuing separate solicitations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, including chloroprocaine and related local anesthetics, with proposals due March 26, 2026. The solicitation requires manufacturers to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded products effective July 1, 2026, and extends across participating jurisdictions in Minnesota, Oregon, and other MMCAP member states. Vendors must certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, maintain contractual relationships with at least two of the three authorized wholesalers, and provide competitive pricing under flat-price, net-price, or WAC-minus formats; evaluation weights 75 percent on price competitiveness, with administrative compliance and EDI capability accounting for the remainder. The RFP discloses no specific set-aside designations.